Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Update on research and tr… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Update on research and treatment of premenstrual dysphoric disorder.

Artikel i vetenskaplig tidskrift
Författare Joanne Cunningham
Kimberly Ann Yonkers
Shaughn O'Brien
Elias Eriksson
Publicerad i Harvard review of psychiatry
Volym 17
Nummer/häfte 2
Sidor 120-37
ISSN 1465-7309
Publiceringsår 2009
Publicerad vid Institutionen för neurovetenskap och fysiologi, sektionen för farmakologi
Sidor 120-37
Språk en
Länkar dx.doi.org/10.1080/1067322090289183...
Ämnesord Female, Humans, Premenstrual Syndrome, drug therapy, epidemiology, psychology, Quality of Life, psychology, Severity of Illness Index, Social Behavior, Somatoform Disorders, diagnosis, epidemiology, psychology
Ämneskategorier Farmakologi och toxikologi

Sammanfattning

Many women in their reproductive years experience some mood, behavioral. or physical symptoms in the week prior to menses. Variability exists in the level of symptom burden in that some women experience mild symptoms, whereas a small minority experience severe and debilitating symptoms. For an estimated 5%-8% of premenopausal women, work or social functioning are affected by severe premenstrual syndrome. Many women in this group meet diagnostic criteria for premenstrual dysphoric disorder (PMDD). Among women who suffer from PMDD, mood and behavioral symptoms such as irritability, depressed mood, tension, and labile mood dominate. Somatic complaints, including breast tenderness and bloating, also can prove disruptive to women's overall functioning and quality of life. Recent evidence suggests that individual sensitivity to cyclical variations in levels of gonadal hormones may predispose certain women to experience these mood, behavioral, and somatic symptoms. Treatments include: antidepressants of the serotonin reuptake inhibitor class, taken intermittently or throughout the menstrual cycle; medications that suppress ovarian cyclicity; and newer oral contraceptives with novel progestins.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?